FDA Brief

Warning letters Drugs

FDA warning letter to

LCC Ltd.

High riskIssued Nov 21, 2024Posted Dec 3, 2024Center for Drug Evaluation and Research (CDER)

FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.

What happened

FDA inspected LCC Ltd.'s drug manufacturing facility in Eumseong-gun, Chungcheongbuk-do, South Korea, from March 18 to 22, 2024, and found violations of current good manufacturing practice (CGMP). Investigators found missing identity testing for high-risk components such as glycerin and propylene glycol, inadequate quality-unit oversight, and discarded, lost, or incomplete laboratory data, including a failed HPLC result that was not investigated. FDA also reviewed product labels and the website www.soloralcare.com and found that SOL and Oriox mouthwash products were unapproved new drugs and misbranded.

What FDA found

  1. LCC did not perform adequate identity testing on each incoming component lot and relied on supplier certificates of analysis without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. LCC did not test high-risk glycerin and propylene glycol lots for diethylene glycol and ethylene glycol contamination.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. LCC's quality unit lacked adequate procedures and failed to ensure stability testing, laboratory controls, master production records, and batch records.

    21 CFR 211.22(a), 211.22(d), 211.166(a), 211.160(b), 211.186(a), 211.188(b)
  4. LCC's laboratory records were incomplete and unreliable; original pH and HPLC data were discarded, an out-of-specification result was not investigated, and electronic raw data were lost.

    21 CFR 211.194(a)
  5. LCC marketed SOL and Oriox mouth rinses as drugs without FDA approval and outside the applicable over-the-counter conditions.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  6. The two mouthwash products were misbranded because they did not meet the over-the-counter drug requirements and had no approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA asks LCC to provide a full DEG/EG risk assessment, recall or notify customers about affected lots, remediate its quality-unit and data-integrity failures, and address the unapproved and misbranded mouthwash products in its response.

Who should pay attention

  • brands that buy OTC mouthwash from contract manufacturers
  • companies sourcing glycerin or propylene glycol
  • US importers and retailers of SOL or Oriox mouthwash

This is a summary. Read the original letter on fda.gov.

LCC Ltd.'s FDA history

  1. LCC Ltd.

    LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.

    High risk

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk